Skip to content

Uromodulin in Rheumatoid Arthritis

Uromodulin Levels in Rheumatoid Arthritis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03972098
Enrollment
86
Registered
2019-06-03
Start date
2017-05-01
Completion date
2018-06-01
Last updated
2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

uromodulin

Brief summary

The aim of the present study was to evaluate the levels of uromodulin in rheumatoid arthritis (RA) and to investigate whether it was correlated with baseline clinical characteristics. In addition CKD epi,MDRD,urine microalbuminuria,pH,serum urea, creatinine,CRP (C-Reactive protein) were measured.The participants consist of ; %68 patients,% 32 control group.

Detailed description

Uromodulin, also known as Tamm-Horsfall protein, is a protein abundantly excreted in the urine in healthy individuals. It is synthesized in the thick ascending limb of Henle (TALH) and the early distal convoluted tubule. Its biologic function is still obscure; however, some experimental studies indicated that it might serve as an important urinary defense factor against bacterial colonization and stone formation. There are controversial publications on the frequencies of urinary tract infections and nephrolithiasis in patients with mutations of uromodulin gene. Deposition of mutated uromodulin in the urinary system may lead to tubular cell dysfunction and apoptosis. These alterations may subsequently cause tubular atrophy and interstitial fibrosis . Moreover, the release of abnormal uromodulin after apoptosis through basolateral secretion may elicit an immune response which may give rise to an immune-mediated tubulointerstitial nephritis . Uromodulin can activate the other components of the immune system and may modulate the inflammatory and immune responses through different mechanisms . Experimental studies yielded that uromodulin negative mice displayed splenomegaly with infiltration of white pulp by macrophages and increased levels of TNF-α and interleukin-1 . Rheumatoid arthritis is a systemic autoimmune condition that may eventually result in the joint damage, disability and premature mortality.

Interventions

None listed

Sponsors

neval aksoy
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients who diagnosed of rheumatoid arthritis as criteria of ACR/EULAR 2010. * All patients age range is 18-80 years.

Exclusion criteria

: * Renal failure * Hepatic insufficiency * Diabetes mellitus * Other collagen vascular diseases, * History of smoking and consumption of alcohol

Design outcomes

Primary

MeasureTime frameDescription
Patients with rheumatoid arthritis1 dayThe diagnosis of RA was based on the criteria the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) in 2010. Patients selected 1. have at least 1 joint with definite clinical synovitis (swelling) 2. with the synovitis not better explained by another disease Classification criteria for RA (score-based algorithm: add score of categories A-D; a score of \>6/10 is needed for classification of a patient as having definite RA)
A.joint involvement1 day1 large joint (score 0) 2-10 large joints (score 1) 1-3 small joints (with or without involvement of large joints)#(score2) 4-10 small joints (with or without involvement of large joints)(score 3) 10 joints (at least 1 small joint) (score 5)
B.Serology (at least 1 test result is needed for classification)1 dayNegative RF and negative ACPA (Score 0) Low-positive RF or low-positive ACPA( anticitrullinated protein antibody) (score 2) High-positive RF(rheumatoid factor) or high-positive ACPA (score 3)
C.Acute-phase reactants (at least 1 test result is needed for classification)1 dayNormal CRP (C-reactive protein and normal) and normal ESR (erythrocyte sedimentation rate) (score 0) Abnormal CRP or abnormal ESR (score1)
D.Duration of symptoms1 day\<6 weeks (score 0) \>6 weeks (score 1)
Uromodulin measure1 dayFirst urine sample taken in the morning

Secondary

MeasureTime frameDescription
CKD-EPI (Chronic Kidney Disease Epidemiology Colloboration)1 dayFor estimating the glomerular filtration rate
Microalbuminuria measure1 dayFirst urine sample taken in the morning
MDRD (Modification of Diet in Renal Disease)1 dayFor estimating the glomerular filtration rate
Urea measure1 dayFasting blood samples taken in the morning
Creatinine measure1 dayFasting blood samples taken in the morning
Sedimantation measure1 dayFasting blood samples taken in the morning
pH measure1 dayFirst urine sample taken in the morning

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026